Full-Time
Delivers value-based care through analytics
No salary listed
Pune, Maharashtra, India
Remote
Must work until 2 p.m. Eastern Time / 11:30 p.m. India Standard Time.
Bachelor's
See people who can refer or advise you
Evolent Health helps healthcare organizations transition to value-based care by pairing technology, analytics, and clinical expertise to improve patient outcomes while lowering costs. It partners with health systems, physician groups, and health plans to deliver data-driven care coordination, population health management, and risk-adjustment services. The company’s offerings include software platforms, analytics, and clinical support that enable more efficient care delivery, shared savings programs, and performance-based incentives. Compared with competitors, Evolent emphasizes end-to-end collaboration with clients and a diversified client base, combining technology with hands-on clinical and operational expertise to drive measurable outcomes. Its goal is to help clients succeed in value-based models by delivering better patient care at lower total costs.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Arlington, Virginia
Founded
2011
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Flexible Work Hours
Hybrid Work Options
Performance Bonus
Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.
Evolent Health reported strong second-quarter results, beating revenue expectations with $652.5 million versus the anticipated $596.7 million, representing 46.9% year-on-year growth. The company also surpassed adjusted earnings per share and EBITDA forecasts. CEO Seth Blackley attributed the performance to successful contract launches with Highmark and robust customer renewals. Clinical engagement metrics for new partnerships with Aetna and Highmark exceeded targets, demonstrating strong execution in value-based care solutions. The company raised its full-year revenue guidance to $2.65 billion at the midpoint, up 6% from the previous $2.5 billion forecast. EBITDA guidance remained at $127.5 million. During the earnings call, management addressed analyst questions about reserving processes, margin trends in new contracts, and pipeline development. Blackley noted the business pipeline has refilled with several large national plans under consideration, particularly in oncology services.
Evolent Health reported Q2 2026 revenue of $652.5 million, up 46.9% year-on-year and beating analyst estimates by 9.4%. The healthcare solutions company's full-year revenue guidance of $2.65 billion came in 5.9% above consensus. CEO Seth Blackley highlighted the successful launch of the Highmark contract and strong clinical engagement metrics for new partnerships with Aetna and Highmark. The company's Auth Intelligence automation platform contributed to operational efficiency gains. Management pointed to expansion of its oncology Performance Suite and accelerated deployment of its AI-enabled authorisation platform as key growth drivers. Blackley stated Q2 represented "a tipping point in our AI journey" as efforts moved beyond pilot phases to meaningful scale. The company expects cost-saving initiatives and improved operating leverage to offset headwinds from Medicaid and exchange membership pressures.
Evolent Health reported strong second-quarter 2026 results, with total revenue reaching $653 million, up 31% from the previous quarter. Adjusted EBITDA rose 27% quarter-over-quarter to $28 million. The healthcare technology company raised its full-year 2026 revenue guidance to between $2.6 billion and $2.7 billion. It tightened adjusted EBITDA guidance to a range of $120 million to $135 million. Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualised revenue. The company also secured a contract extension with a regional Blue Cross plan. The firm ended Q2 with $115.7 million in unrestricted cash and $808.3 million of net debt. For 2027, Evolent expects revenue growth exceeding 25%.
Evolent Health reported Q1 revenues of $496.2 million, up 2.6% year on year, but falling short of analysts' expectations by 6.9%. The healthcare technology company, which provides specialty care management services for patients with complex conditions, delivered mixed results with an earnings per share beat but a significant revenue miss. The healthcare technology for providers sector showed overall strength in Q1, with the four tracked stocks beating revenue consensus estimates by 1.1% on average. Share prices have risen 7.7% on average since earnings results. Despite having the weakest performance against analyst estimates and slowest revenue growth in the group, Evolent Health raised its full-year guidance the most. The stock has climbed 21.5% since reporting and currently trades at $4.65.